James C-H Yang
Overview
Explore the profile of James C-H Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis C, et al.
Future Oncol
. 2019 Jul;
15(20):2371-2383.
PMID: 31354046
We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT...
12.
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, et al.
Lung Cancer
. 2019 May;
132:126-131.
PMID: 31097085
Objectives: With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in...
13.
Hochmair M, Morabito A, Hao D, Yang C, Soo R, Yang J, et al.
Future Oncol
. 2018 Oct;
14(27):2861-2874.
PMID: 30336693
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective,...
14.
Ramalingam S, Yang J, Lee C, Kurata T, Kim D, John T, et al.
J Clin Oncol
. 2017 Aug;
36(9):841-849.
PMID: 28841389
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase...
15.
Gandhi L, Ou S, Shaw A, Barlesi F, Dingemans A, Kim D, et al.
Eur J Cancer
. 2017 Jun;
82:27-33.
PMID: 28646771
Background: Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metastases,...
16.
Jenkins S, Yang J, Ramalingam S, Yu K, Patel S, Weston S, et al.
J Thorac Oncol
. 2017 Apr;
12(7):1061-1070.
PMID: 28428148
Introduction: Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive, costly, and not always feasible for patients with late-stage disease. The clinical utility of the cobas EGFR Mutation...
17.
Schuler M, Wu Y, Hirsh V, OByrne K, Yamamoto N, Mok T, et al.
J Thorac Oncol
. 2016 Jan;
11(3):380-90.
PMID: 26823294
Introduction: Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective clinical trials. The studies, phase III...
18.
Yang J, Sequist L, Geater S, Tsai C, Mok T, Schuler M, et al.
Lancet Oncol
. 2015 Jun;
16(7):830-8.
PMID: 26051236
Background: Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common...